Research programme: botulinum toxin vaccine - Soligenix

Drug Profile

Research programme: botulinum toxin vaccine - Soligenix

Alternative Names: BT-VACC

Latest Information Update: 05 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Thomas Jefferson University
  • Developer Soligenix
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Botulism

Most Recent Events

  • 28 Aug 2007 This vaccine is still in active development
  • 11 Apr 2006 Preclinical data have been added to the Viral infections immunogenicity section
  • 14 May 2003 Preclinical trials in Botulism in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top